Semaglutide

Overview

Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1 (GLP-1) developed by Novo Nordisk. It activates the GLP-1 receptor, which plays a role in blood sugar regulation, appetite signaling, and gastric motility. Semaglutide's molecular structure includes modifications — specifically, a fatty acid chain that enables albumin binding — that extend its half-life to approximately seven days, allowing once-weekly administration.

Semaglutide is one of the most extensively studied peptides in clinical medicine, with hundreds of clinical trials conducted globally. It is available in both injectable and oral formulations across multiple approved indications. As of late 2025, Novo Nordisk announced FDA approval of an oral semaglutide formulation for chronic weight management, making it the first oral GLP-1 medication approved for that indication.

Research context

Semaglutide has been evaluated across several major clinical trial programs. The SUSTAIN program studied injectable semaglutide in adults with type 2 diabetes. The STEP program evaluated its effects on weight management in adults with obesity or overweight. The PIONEER program focused on oral semaglutide for type 2 diabetes. The SELECT trial assessed cardiovascular outcomes in adults with overweight or obesity and established cardiovascular disease.

These programs have collectively enrolled tens of thousands of participants across dozens of countries, making semaglutide one of the most clinically validated peptides in current use. Research has also explored its effects on kidney outcomes, liver fat, and additional cardiometabolic endpoints.

Safety and regulatory framing

FDA-approved as Ozempic (T2D), Wegovy (weight management), and Rybelsus (oral T2D)

Semaglutide is an FDA-approved prescription medication available under several brand names: Ozempic (injectable, for type 2 diabetes), Wegovy (injectable and oral, for chronic weight management), and Rybelsus (oral, for type 2 diabetes). Each formulation has its own approved indication, dosing, and prescribing information.

As with all prescription medications, semaglutide carries labeled warnings and potential adverse effects described in its prescribing information. Regulatory approval and availability vary internationally. Compounded versions of semaglutide have been the subject of ongoing regulatory and legal action in the United States. Readers should consult a licensed healthcare provider for any decisions about treatment.

References

1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM (2021) ↗
   New England Journal of Medicine
2. SELECT Cardiovascular Outcomes Trial ↗
   ClinicalTrials.gov
3. PIONEER 1 Trial — Oral Semaglutide in Type 2 Diabetes ↗
   PubMed
4. Ozempic (Semaglutide) Prescribing Information — FDA Label ↗
   FDA.gov
5. FDA Approval of Wegovy for Chronic Weight Management (2021) ↗
   FDA.gov